The Food and Drug Administration approved Ion Beam Applications' new super conducting accelerator for Proteus One, an intensity modulated proton therapy system used to treat patients with cancer.
Proteus One is a compact proton therapy that offers optimized Pencil Beam Scanning and image guidance. So far, IBA has signed 13 contracts to provide the system to healthcare systems throughout the world.
"Any hospital considering proton therapy can now afford it through the Proteus One's lower capital and operating costs without making any clinical compromise," Beth Klein, president of IBA Proton Therapy North America, said. "Ultimately, this will make proton therapy more accessible to the radiation therapy patients in the United States who can benefit from it."
IBA expects to launch the proton therapy system in less than a year.
More articles on medical devices:
FDA approves expanded indications of heart valve
Medtronic issues warning for heart valve delivery system following 19 deaths
FDA notifies 14 international medical device companies about regulatory violations